ANA LLUCH HERNANDEZ-rekin lankidetzan egindako argitalpenak (8)

2021

  1. Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation

    ESMO open, Vol. 6, Núm. 3, pp. 100148

2016

  1. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 160, Núm. 1, pp. 69-77

2003

  1. Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations.

    Human mutation, Vol. 22, Núm. 5, pp. 417-418

1994

  1. Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma

    Oncology (Switzerland), Vol. 51, Núm. 4, pp. 352-355

  2. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy

    Annals of Oncology, Vol. 5, Núm. 9, pp. 854-857

1987

  1. Adjuvant chemotherapy with adriamycin, fluorouracil, cyclophosphamide, methotrexate, with or without tamoxifen in operable breast cancer

    Tumori, Vol. 73, Núm. 5, pp. 467-473

  2. Receptores de estrógeno y progesterona en el cáncer de mama.

    Medicina Clinica, Vol. 89, Núm. 11, pp. 456-459

  3. Tratamiento del cáncer de mama localmente avanzado.

    Medicina Clinica, Vol. 89, Núm. 1, pp. 7-10